Scpharmaceuticals Short Term Debt vs Total Liab Analysis
SCPH Stock | USD 4.83 0.26 5.69% |
Scpharmaceuticals financial indicator trend analysis is much more than just breaking down Scpharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Scpharmaceuticals is a good investment. Please check the relationship between Scpharmaceuticals Short Term Debt and its Total Liab accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Scpharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.
Short Term Debt vs Total Liab
Short Term Debt vs Total Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Scpharmaceuticals Short Term Debt account and Total Liab. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Scpharmaceuticals' Short Term Debt and Total Liab is -0.2. Overlapping area represents the amount of variation of Short Term Debt that can explain the historical movement of Total Liab in the same time period over historical financial statements of Scpharmaceuticals, assuming nothing else is changed. The correlation between historical values of Scpharmaceuticals' Short Term Debt and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Term Debt of Scpharmaceuticals are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Short Term Debt i.e., Scpharmaceuticals' Short Term Debt and Total Liab go up and down completely randomly.
Correlation Coefficient | -0.2 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Short Term Debt
Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Most indicators from Scpharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Scpharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Scpharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.As of now, Scpharmaceuticals' Selling General Administrative is increasing as compared to previous years. The Scpharmaceuticals' current Enterprise Value is estimated to increase to about 246.7 M, while Issuance Of Capital Stock is projected to decrease to under 31.9 M.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 2.6M | 3.3M | 8.1M | 8.5M | Depreciation And Amortization | 364K | 2.6M | 626K | 746.3K |
Scpharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Scpharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Scpharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 77.3M | 109.0M | 79.0M | 124.2M | 94.5M | 90.6M | |
Other Current Liab | 3.7M | 4.8M | 26K | 5.3M | 9.0M | 9.4M | |
Total Current Liabilities | 5.2M | 9.3M | 14.8M | 7.4M | 13.1M | 8.3M | |
Total Stockholder Equity | (129.5M) | (161.7M) | (189.7M) | (226.5M) | 37.2M | 39.1M | |
Other Liab | 58K | 219K | 367K | 7.5M | 8.7M | 9.1M | |
Net Tangible Assets | 51.4M | 82.2M | 63.1M | 72.4M | 83.3M | 54.8M | |
Property Plant And Equipment Net | 1.3M | 908K | 479K | 620K | 1.5M | 1.0M | |
Net Debt | (52.5M) | (85.1M) | (56.6M) | (33.7M) | (6.5M) | (6.9M) | |
Retained Earnings | (129.5M) | (161.7M) | (189.7M) | (226.5M) | (281.3M) | (267.3M) | |
Accounts Payable | 1.1M | 1.7M | 544K | 1.5M | 4.0M | 4.2M | |
Cash | 72.8M | 105.3M | 74.3M | 71.1M | 46.8M | 75.7M | |
Non Current Assets Total | 1.6M | 1.2M | 762K | 887K | 1.5M | 1.2M | |
Non Currrent Assets Other | 148K | 132K | 283K | 267K | 82.0K | 159.4K | |
Other Assets | 330K | 1.1M | 283K | 267K | 1.0 | 0.95 | |
Cash And Short Term Investments | 72.8M | 105.3M | 75.5M | 118.4M | 76.0M | 85.2M | |
Net Receivables | 655K | 479K | 310K | 2.3M | 4.5M | 4.7M | |
Common Stock Shares Outstanding | 18.6M | 24.6M | 27.4M | 28.4M | 38.5M | 22.2M | |
Liabilities And Stockholders Equity | (103.5M) | (134.8M) | (167.1M) | (174.8M) | 94.5M | 99.2M | |
Non Current Liabilities Total | 20.7M | 17.6M | 7.7M | 44.3M | 44.1M | 29.9M | |
Capital Surpluse | 180.8M | 243.8M | 246.2M | 298.9M | 343.8M | 182.1M | |
Inventory | 1.6M | 2.4M | 0.0 | 1.2M | 8.8M | 9.3M | |
Other Current Assets | 94K | 121K | 24K | 1.4M | 3.6M | 3.8M | |
Other Stockholder Equity | 598K | (2K) | (4K) | (35K) | 318.6M | 334.5M | |
Total Liab | 25.9M | 26.9M | 22.6M | 51.8M | 57.3M | 38.2M | |
Property Plant And Equipment Gross | 1.3M | 93K | 649K | 808K | 1.5M | 769.8K | |
Total Current Assets | 75.6M | 107.8M | 78.3M | 123.3M | 92.9M | 89.4M | |
Accumulated Other Comprehensive Income | (600K) | (102K) | 1K | (1K) | 32K | (1.1K) | |
Property Plant Equipment | 1.3M | 908K | 69K | 54K | 48.6K | 46.2K | |
Non Current Liabilities Other | 58K | 219K | 367K | 35K | 177K | 147.7K | |
Short Long Term Debt Total | 20.3M | 20.2M | 17.6M | 37.4M | 40.3M | 24.9M | |
Long Term Debt | 18.9M | 16.9M | 7.4M | 36.8M | 38.8M | 21.2M | |
Long Term Debt Total | 18.9M | 16.9M | 7.4M | 36.8M | 42.3M | 44.4M | |
Capital Lease Obligations | 1.4M | 940K | 476K | 574K | 1.5M | 963.3K | |
Net Invested Capital | 70.3M | 101.4M | 73.6M | 109.2M | 76.0M | 72.5M | |
Net Working Capital | 70.4M | 98.5M | 63.4M | 115.9M | 79.8M | 71.8M | |
Short Term Debt | 407K | 2.9M | 10.3M | 567K | 176K | 167.2K |
Currently Active Assets on Macroaxis
When determining whether Scpharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Scpharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Scpharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Scpharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Scpharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Complementary Tools for Scpharmaceuticals Stock analysis
When running Scpharmaceuticals' price analysis, check to measure Scpharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scpharmaceuticals is operating at the current time. Most of Scpharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Scpharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scpharmaceuticals' price. Additionally, you may evaluate how the addition of Scpharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |
Is Scpharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Scpharmaceuticals. If investors know Scpharmaceuticals will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Scpharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.42) | Revenue Per Share 0.454 | Quarterly Revenue Growth 1.958 | Return On Assets (0.36) | Return On Equity (1.15) |
The market value of Scpharmaceuticals is measured differently than its book value, which is the value of Scpharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Scpharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Scpharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Scpharmaceuticals' market value can be influenced by many factors that don't directly affect Scpharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Scpharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Scpharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Scpharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.